Lindy Biosciences

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sarepta Obtains Rights To Seven Arrowh

The US FDA’s back-to-back approvals of Genentech ’s Tecentriq Hybreza and Ocrevus Zunovo place a spotlight on biologics delivery specialist Halozyme Therapeutics , whose Enhanze technology has now b

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip ‘s global team, in this podcast version of Five Must-Know Things. This ep